These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rationale for aggressive lipid lowering: evidence from clinical trials. Farmer JA Expert Rev Cardiovasc Ther; 2004 May; 2(3):305-9. PubMed ID: 15151477 [No Abstract] [Full Text] [Related]
6. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). HMG-CoA reductase inhibitors: a review of published clinical trials and pharmacoeconomic evaluations. Int J Technol Assess Health Care; 1998; 14(2):396-8. PubMed ID: 9678976 [No Abstract] [Full Text] [Related]
7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046 [TBL] [Abstract][Full Text] [Related]
8. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292 [TBL] [Abstract][Full Text] [Related]
9. It's the cholesterol, stupid! Roberts WC Am J Cardiol; 2010 Nov; 106(9):1364-6. PubMed ID: 21029840 [No Abstract] [Full Text] [Related]
10. Cholesterol and coronary events. The current thinking. Jones PH Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618 [TBL] [Abstract][Full Text] [Related]
12. Review of efficacy of rosuvastatin 5 mg. Teramoto T; Watkins C Int J Clin Pract; 2005 Jan; 59(1):92-101. PubMed ID: 15707472 [TBL] [Abstract][Full Text] [Related]
13. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. Hobbs FD Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease. Poussa H; Strandberg TE; Tikkanen I; Kauhanen P; Lepäntalo M Scand Cardiovasc J; 2007 Jun; 41(3):138-41. PubMed ID: 17487761 [TBL] [Abstract][Full Text] [Related]
15. Drug prevention of hypertension. Up to a point. Schachter M BMJ; 2009 Jun; 338():b2601. PubMed ID: 19564185 [No Abstract] [Full Text] [Related]
16. What is the most effective strategy for managing diabetic dyslipidaemia? Reasner CA Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442 [TBL] [Abstract][Full Text] [Related]
17. Statins for high-risk patients without heart disease or high cholesterol. Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400 [No Abstract] [Full Text] [Related]
18. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170 [TBL] [Abstract][Full Text] [Related]
19. [Guideline for management of lipid metabolism]. Ishibashi S Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068 [No Abstract] [Full Text] [Related]
20. Appropriate clinical use of statins: a discussion of the evidence, scope, benefits, and risk. Perlmutter D; Golomb B; Sinatra S; Campbell AW Altern Ther Health Med; 2013; 19 Suppl 1():14-25. PubMed ID: 23981463 [No Abstract] [Full Text] [Related] [Next] [New Search]